Utama › Neuroblastoma › Illinois
Kajian klinikal Neuroblastoma di Illinois
6 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- dan 4 lagi
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
- Ann & Robert H. Lurie Children's Hospital of Chicago and the Stanley Manne Children's Research Institute, Chicago
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 3 Sep 2026 · NCT03088020Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- dan 4 lagi
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Comer Children's Hospital, University of Chicago, Chicago
Mengambil pesertaFasa 2
Umur 1 hingga 31 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06450041Neuroblastoma Biology Study
- University of Chicago, Comer Children's Hospital, Chicago
Mengambil pesertaKajian pemerhatian
31 Days – 99 Years · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01587300Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.